ASN: Connective Tissue Growth Factor Is A Potential Marker For Progressive Diabetic Nephropathy
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




ASN: Connective Tissue Growth Factor Is A Potential Marker For Progressive Diabetic Nephropathy

By Maggie Schwarz
Special to DG News

PHILADELPHIA, PA -- November 4, 2002 -- Plasma and urine connective tissue growth factor in diabetic patients correlate with systolic blood pressure and urinary albumin excretion.

Ayad A. Jaffa, MD, and colleagues at the Medical University of South Carolina, Charleston, South Carolina, United States, investigated the role of connective tissue growth factor (CTGF) as a marker of diabetic nephropathy and presented results here November 3 at the 35th Annual Meeting of the American Society of Nephrology (ASN).

The investigators measured circulating levels and urinary excretion rate of CTGF in a cohort of 123 type 1 diabetic patients by three newly developed enzyme-linked immunosorbent assays specific for CTGF and fragments of CTGF generated by its proteolysis.

Plasma CTGF fragment levels in patients with albumin excretion rate (AER) greater than 300 mg/dL were 23.6 ng/mL versus 13.4 ng/mL in patients with AER of 40 - 299 mg/dL and 14.9 ng/mL in patients with normal AER less than 40 mg/dL (p<.0001). The excretion rate of CTGF fragments in patients with AER >300 mg/dL was 8.8 mg/24 hours versus 2.94 mg/24 hours in patients with AER of 40 to 299 mg/dL and 4.6 mg/24 hours in patients with normal AER less than 40 mg/dL (p<.05).

Diabetic nephropathy characterized by albuminuria is one of the major complications of type 1 diabetes and the leading cause of chronic end-stage renal disease. Though the association of chronic hyperglycemia and diabetic nephropathy is established, factors linking hyperglycemia and albuminuria have not been defined.

Dr. Jaffa concluded that CTGF markers in the plasma and urine of diabetic patients positively correlate with systolic blood pressure and albumin excretion rate. CTGF is a potential risk factor or marker for progressive diabetic nephropathy or related vascular disease.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities